{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"227","value":"525"},{"groupId":"OG001","spread":"318","value":"611"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"description":"Maximum Ctrough was defined as the serum predose concentration of daratumumab on Cycle 3 Day 1.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received daratumumab intravenous infusion (Dara IV) 16 milligrams per kilogram (mg/kg) once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks thereafter until disease progression, unacceptable toxicity, withdrawal of consent, the investigator decides to stop treatment, or the start of subsequent anticancer therapy. The duration for each cycle was 28 days.","id":"OG000","title":"Daratumumab IV"},{"description":"Participants received daratumumab 1800 mg subcutaneous injection (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Units per milliliter (U/mL), once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks thereafter until disease progression, unacceptable toxicity, withdrawal of consent, the investigator decides to stop treatment, or the start of subsequent anticancer therapy. The duration for each cycle was 28 days.","id":"OG001","title":"Daratumumab SC"}],"paramType":"MEAN","populationDescription":"Pharmacokinetics (PK) population included participants who received at least 1 administration of study drug and had at least 1 PK sample concentration value after the first dose administration. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Predose on Cycle 3 Day 1 (each cycle of 28 days)","title":"Maximum Trough Concentration (Ctrough) of Daratumumab","type":"PRIMARY","unitOfMeasure":"micrograms per milliliter (mcg/mL)"}